Back to mobile site
Get it on Google Play

Amneal gets FDA approval for generic glaucoma treatment

September 23, 2025 8:00 AM EDT Send to a Friend
Amneal Pharmaceuticals Inc. (NASDAQ: AMRX) received U.S. Food and Drug Administration approval for its generic version of bimatoprost ophthalmic solution ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login